Thyme Care secured $97 million in its latest Series D funding round led by major healthcare investors including CVS Health Ventures, Foresite Capital, Morgan Health, and Humana. This investment brings the company’s total funding to $275 million, underscoring confidence in its value-based cancer care model. Thyme Care’s approach aims to improve patient outcomes by aligning care delivery with value metrics, potentially transforming oncology management in clinical practice.